Profile
Michael Mulqueen worked as the Global Head-Alliance Management at Roche Holding AG from 1992 to 2005.
He then worked as the Vice President-European Operations at Synosia Therapeutics AG, followed by Head-Business Development & Licensing at Silence Therapeutics Plc.
From 2006 to 2011, he served as the Vice President-Business Development at Synosia Therapeutics, Inc. and from 2011 to 2015, he worked as the Vice President-Business Development at Biotie Therapies, Inc. Mr. Mulqueen also has an undergraduate degree from The University of Liverpool.
Former positions of Michael Mulqueen
| Companies | Position | End |
|---|---|---|
| Biotie Therapies, Inc. | Corporate Officer/Principal | 2014-12-31 |
Synosia Therapeutics, Inc.
 Synosia Therapeutics, Inc. Medical SpecialtiesHealth Technology Synosia Therapeutics, Inc. used to develop products for unmet medical needs in psychiatry and neurology. The company was founded in December 2005 and was headquartered in San Francisco, CA. | Corporate Officer/Principal | 2010-12-31 |
| ROCHE HOLDING AG | Corporate Officer/Principal | 2004-12-31 |
| SILENCE THERAPEUTICS PLC | Corporate Officer/Principal | - |
Synosia Therapeutics AG
 Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | Chief Operating Officer | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ROCHE HOLDING AG | Health Technology |
| SILENCE THERAPEUTICS PLC | Commercial Services |
| Private companies | 3 |
|---|---|
Synosia Therapeutics AG
Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | Health Technology |
Synosia Therapeutics, Inc.
Synosia Therapeutics, Inc. Medical SpecialtiesHealth Technology Synosia Therapeutics, Inc. used to develop products for unmet medical needs in psychiatry and neurology. The company was founded in December 2005 and was headquartered in San Francisco, CA. | Health Technology |
| Biotie Therapies, Inc. |
- Stock Market
- Insiders
- Michael Mulqueen
